Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis and Low Cardiovascular Risk: The Role of von Willebrand Factor Activity
| Autor: | Dejana Stanisavljevic, Toplica Lepic, Gorica G. Ristić, Vesna Subota, Milan Petronijevic, Arsen D. Ristić, D Stefanovic, B Glisic |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
lcsh:Medicine Inflammation Fibrinogen Arthritis Rheumatoid Von Willebrand factor Risk Factors hemic and lymphatic diseases von Willebrand Factor medicine Humans In patient lcsh:Science Multidisciplinary biology business.industry lcsh:R Middle Aged medicine.disease Atherosclerosis Antirheumatic Agents Early Diagnosis Methotrexate Cardiovascular Diseases Subclinical atherosclerosis Rheumatoid arthritis Immunology biology.protein lcsh:Q Female medicine.symptom business circulatory and respiratory physiology medicine.drug Research Article |
| Zdroj: | PLoS ONE PLoS ONE, Vol 10, Iss 8, p e0130462 (2015) |
| ISSN: | 1932-6203 |
| Popis: | Background To evaluate association between von Willebrand factor (vWF) activity, inflammation markers, disease activity, and subclinical atherosclerosis in patients with rheumatoid arthritis (RA) and low cardiovascular risk. Methods Above mentioned parameters were determined in blood samples of 74 non-diabetic, normotensive, female subjects, with no dyslipidemia(42 patients, 32 matched healthy controls, age 45.3±10.0 vs. 45.2±9.8 years). Intima-media thickness (IMT) was measured bilaterally, at common carotid, bifurcation, and internal carotid arteries. Subclinical atherosclerosis was defined as IMT>IMTmean+2SD in controlsat each carotid level and atherosclerotic plaque as IMT>1.5 mm. Majority of RA patients were on methotrexate (83.3%), none on steroids >10 mg/day or biologic drugs. All findings were analysed in the entire study population and in RA group separately. Results RA patients with subclinical atherosclerosis had higher vWF activity than those without (133.5±69.3% vs. 95.3±36.8%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|